Trial reportAlimentary pharmacology & therapeutics2017
Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence.
Trial report in Alimentary pharmacology & therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 23 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Double-blind, Randomized, Placebo-controlled, Parallel Group, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis
Double-blind, Dose-response, Randomised, Placebo-controlled, Parallel Group, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis
Who cites it
23 citing papers in PubMed, 5 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Long-term outcomes in recurrent diverticulitis: a systematic review of treatment strategies and recurrence rates.International journal of colorectal disease · 2026Pooled it
- German guideline diverticular disease/diverticulitis: Part II: Conservative, interventional and surgical management.United European gastroenterology journal · 2022Guideline
- Recurrence of Uncomplicated Diverticulitis: A Meta-Analysis.Medicina (Kaunas, Lithuania) · 2022Pooled it
- Mesalazine for People with Diverticular Disease: A Systematic Review of Randomized Controlled Trials.Canadian journal of gastroenterology & hepatology · 2018Pooled it
- Mesalamine (5-ASA) for the prevention of recurrent diverticulitis.The Cochrane database of systematic reviews · 2017Pooled it
- Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence.Alimentary pharmacology & therapeutics · 2017Trial
- Evidence-based clinical practice guidelines for diagnosis and medical management of acute colonic diverticulitis developed by the Korean Association for the Study of Intestinal Diseases (KASID).Intestinal research · 2026Review
- Risk-stratified pharmacologic strategies for secondary prevention after acute diverticulitis: an exploratory narrative review and research framework.Frontiers in surgery · 2026Review
- Unmet needs in treatment of symptomatic uncomplicated diverticular disease and prevention of recurrent acute diverticulitis: a scoping review.Therapeutic advances in gastroenterology · 2024Article
- [Diagnosis and Treatment of Colonic Diverticular Disease].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2022Review
- [Diverticular disease. Clinical appearance, conservative treatment, primary and secondary prophylaxis].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2021Review
- Diverticulitis: An Update From the Age Old Paradigm.Current problems in surgery · 2020Review
- Observational
- Italian nationwide survey of pharmacologic treatments in diverticular disease: Results from the REMAD registry.United European gastroenterology journal · 2019Article
- Mesalamine (5-ASA) for the prevention of recurrent diverticulitis (Review).Techniques in coloproctology · 2019Review
- Epidemiology, Pathophysiology, and Treatment of Diverticulitis.Gastroenterology · 2019Review
- Diverticular disease management in primary care: How do estimates from community-dispensed antibiotics inform provision of care?PloS one · 2019Article
- Recent advances in understanding and managing diverticulitis.F1000Research · 2018Review
- Treatment of diverticular disease: an update on latest evidence and clinical implications.Drugs in context · 2018Review
- Management of colonic diverticular disease in the third millennium: Highlights from a symposium held during the United European Gastroenterology Week 2017.Therapeutic advances in gastroenterology · 2018Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
25 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have reached conflicting conclusions regarding the efficacy of mesalazine in the prevention of recurrent diverticulitis.
aimTo investigate the efficacy and safety of mesalazine granules in the prevention of recurrence of diverticulitis after acute uncomplicated diverticulitis.
methodsTwo phase 3, randomised, placebo-controlled, double-blind multicentre trials (SAG-37 and SAG-51) investigated mesalazine granules in patients with prior episodes (<6 months) of uncomplicated left-sided diverticulitis. Patients were randomised to receive either 3 g mesalazine once daily or placebo (SAG-37, n=345) or to receive either 1.5 g mesalazine once daily, 3 g once daily or placebo for 96 weeks (SAG-51, n=330). The primary endpoint was the proportion of recurrence-free patients during 48 weeks (SAG-37 and SAG-51) or 96 weeks (SAG-51) of treatment.
resultsMesalazine did not increase the proportion of recurrence-free patients over 48 or 96 weeks compared to placebo. In SAG-37, the proportion of recurrence-free patients during 48 weeks was 67.9% with mesalazine and 74.4% with placebo (P=.226). In SAG-51, the proportion of recurrence-free patients over 48 weeks was 46.0% with 1.5 g mesalazine, 52.0% with 3 g mesalazine and 58.0% with placebo (P=.860 for 3 g mesalazine vs placebo) and over 96 weeks 6.9%, 9.8% and 23.1% respectively (P=.980 for 3 g mesalazine vs placebo). Patients with only one diverticulitis episode in the year prior to study entry had a lower recurrence risk compared to >1 episode. Safety data revealed no new adverse events.
conclusionMesalazine was not superior to placebo in preventing recurrence of diverticulitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.